Fact based stock research
Chemed (NYSE:CHE)


Chemed stock research in summary

chemed.com


Chemed shares have a SELL rating. While they show above average growth, they are riskily financed, and are bad value. We recommend selling Chemed shares.


Latest Obermatt Ranks


Country USA
Industry Health Care Services
Index D.J. US Health Care
Size class Medium

March 22, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: Chemed

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
32
40
52
23
STOCK GROWTH RANKS
57
27
59
59
STOCK SAFETY RANKS
61
44
58
36
COMBINED STOCK RANKS
48
15
63
33

Last update of Combined Rank: 22-Mar-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Chemed in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 22-Mar-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Chemed; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
42
39
19
19
PROFIT GROWTH
28
66
66
55
STOCK RETURNS
70
48
80
81
CONSOLIDATED RANK: GROWTH
57
27
59
59

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Chemed.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
56
47
48
46
REFINANCING
53
56
39
44
LIQUIDITY
52
50
60
61
CONSOLIDATED RANK: SAFETY
61
44
58
36

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Chemed and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Chemed from March 22, 2018.